TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01709708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine
Description: Marcaine used as a topical local anesthetic to block the SPG by delivering Marcaine directly to the specific area of mucosa associated with the SPG.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline
Study: NCT03210064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib Mesylate Tablets 500 mg qd po

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).
Study: NCT03725449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mySmartCheck
Description: Receive access to mySmartcheck program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT03786406

Intervention type: OTHER
Intervention: No treatment given
Description: No specific intervention is studied. All anti-diabetic and CV medication will be prescribed at the physician's discretion under routine clinical practice conditions.
Study: NCT03518034

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AndroGel®
Description: testosterone administered topically

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo administered topically
Study: NCT00247273

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risedronate
Description: tablet, 5 mg risedronate, once a day for 2 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risedronate
Description: oral, 150 mg risedronate, once a month for 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: oral, 150 mg risedronate, once a month for 2 years
Study: NCT03487315

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: immunoblot
Description: immunoblot
Study: NCT02566109

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fast MRI
Description: The fast MRI is a 10 minute MRI scan that will be used to determine if cardiovascular injury can be detected early while patients are receiving chemotherapy treatment.
Study: NCT04553367

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Meropenem
Description: all patients in both groups receive meropenam and put on the ventilators for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: all patients in both groups receive meropenam and put on the ventilators for 2 weeks
Study: NCT01683838

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fampridine-SR
Description: 25mg bid (twice daily)
Study: NCT03611881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: 4 or 8 weeks of behavioral counseling support to promote smoking cessation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: 2 or 8 weeks of nicotine patch given in a tapering dose of 21 mg, 14 mg, 7 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: 2 or 8 weeks of nicotine patch given in a tapering dose of 21 mg, 14 mg, 7 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: 2 or 8 weeks of nicotine patch given in a tapering dose of 21 mg, 14 mg, 7 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: 2 or 8 weeks of nicotine patch given in a tapering dose of 21 mg, 14 mg, 7 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: 2 or 8 weeks of nicotine patch given in a tapering dose of 21 mg, 14 mg, 7 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: 2 or 8 weeks of nicotine patch given in a tapering dose of 21 mg, 14 mg, 7 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: 2 or 8 weeks of nicotine patch given in a tapering dose of 21 mg, 14 mg, 7 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: 2 or 8 weeks of nicotine patch given in a tapering dose of 21 mg, 14 mg, 7 mg.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Resource
Description: Counselor-facilitated referral to a community-based program to address social needs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Resource
Description: Counselor-facilitated referral to a community-based program to address social needs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Resource
Description: Counselor-facilitated referral to a community-based program to address social needs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Resource
Description: Counselor-facilitated referral to a community-based program to address social needs.
Study: NCT01671709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast sodium
Description: Montelukast sodium tablets 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast sodium
Description: Montelukast sodium tablets 10mg
Study: NCT03797066

Intervention type: DRUG
Group type: OTHER
Intervention: ZEPATIER 50Mg-100Mg Tablet
Description: Zepatier 50/100 OD , with addition of Ribavarin in patients with Genotype 1a and 4 with HCV RNA\> 800,000 iu/ml or baseline NS5A resistance.
Study: NCT01683838

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03303183

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Impression technique
Description: Silicone impression technique

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Ear Scanner
Description: Direct Ear Scanner to scan the ear anatomy
Study: NCT00103610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor plus plerixafor
Description: Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Granulocyte colony-stimulating factor plus placebo
Description: Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
Study: NCT00437632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809
Description: GSK598809 will be available as 5 and 25 mg capsules. Subjects will receive GSK598809 capsules orally with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809
Description: GSK598809 will be available as 5 and 25 mg capsules. Subjects will receive GSK598809 capsules orally with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809
Description: GSK598809 will be available as 5 and 25 mg capsules. Subjects will receive GSK598809 capsules orally with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809
Description: GSK598809 will be available as 5 and 25 mg capsules. Subjects will receive GSK598809 capsules orally with water.
Study: NCT03291730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Art-therapy
Description: May help reduce anxiety of receiving chemotherapy
Study: NCT00437632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809
Description: GSK598809 will be available as 5 and 25 mg capsules. Subjects will receive GSK598809 capsules orally with water.
Study: NCT04553367

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bronchoscopy
Description: Only patients of group B had three times bronchoscopy according to our protocol one at the end of first 5 days, second bronchoscopy at the end of the second 5 days and last one at the end of the studied period

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ventilator
Description: ventilator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ventilator
Description: ventilator
Study: NCT04379609

Intervention type: OTHER
Intervention: Masticatory efficiency
Description: Two-color chewing gum mixing ability test was used to measure masticatory efficiency in the control group, before and after treatment in the experimental group.21 Commercial two-color chewing gum was used.The gum was left on the patient's tongue and he/she was asked to chew 20 times naturally.~After chewing, the gum was put in a transparent plastic bag and squeezed to 1 mm. Both sides of the sample were scanned at 300 dpi resolution on a desktop scanner (HP Deskjet, California, USA) in the same day to prevent the colors from deteriorating due to saliva. For each patient, two sides of scanned images were processed in ViewGum software (version 1.4, Dhal Software, Kifissia, Greece, www.dhal.com) using the method of Halozenitis et al. (2013).22 The value of VOH (variance of hue) was taken as the value of chewing activity. The highness of this value indicates low masticatory efficiency.

Intervention type: OTHER
Intervention: Masticatory efficiency
Description: Two-color chewing gum mixing ability test was used to measure masticatory efficiency in the control group, before and after treatment in the experimental group.21 Commercial two-color chewing gum was used.The gum was left on the patient's tongue and he/she was asked to chew 20 times naturally.~After chewing, the gum was put in a transparent plastic bag and squeezed to 1 mm. Both sides of the sample were scanned at 300 dpi resolution on a desktop scanner (HP Deskjet, California, USA) in the same day to prevent the colors from deteriorating due to saliva. For each patient, two sides of scanned images were processed in ViewGum software (version 1.4, Dhal Software, Kifissia, Greece, www.dhal.com) using the method of Halozenitis et al. (2013).22 The value of VOH (variance of hue) was taken as the value of chewing activity. The highness of this value indicates low masticatory efficiency.
Study: NCT01264068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finished Herbal Product such as Suan Tsao Jen Tang, Jia-Wey Shiau-Yau San
Description: Take medicine every day 3 times, each time 4 grams.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finished Herbal Product such as Suan Tsao Jen Tang, Jia-Wey Shiau-Yau San
Description: Take medicine every day 3 times, each time 4 grams.
Study: NCT00437632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809
Description: GSK598809 will be available as 5 and 25 mg capsules. Subjects will receive GSK598809 capsules orally with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive matching placebo capsules to GSK598809 orally with water.
Study: NCT01405456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone and lifestyle
Description: eplerenone 50mg by mouth daily as well as lifestyle counseling

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo and lifestyle
Description: placebo pill daily and lifestyle counseling
Study: NCT00580684

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pneumococcus conjugate vaccine 7 valent to reduce carriage
Description: plain polisacaride vaccine 23 valent to reduce carriage

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pneumococcus conjugate vaccine 7 valent to reduce carriage
Description: plain polisacaride vaccine 23 valent to reduce carriage
Study: NCT01774968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Regular U-500 Insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Regular U-500 Insulin
Study: NCT01354678

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NOGA XP Cardiac Navigation System
Description: Intramyocardial multiple precision injection of bone marrow mononuclear cells

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: NOGA XP Cardiac Navigation System
Description: Intramyocardial multiple precision injection with placebo
Study: NCT01130142

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPI-926 plus gemcitabine
Description: Daily IPI-926 (oral) at 160 mg plus gemcitabine (infusion) at 1000 mg/m2 once weekly for 3 weeks of a 28 day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IPI-926 plus gemcitabine
Description: Daily IPI-926 (oral) at 160 mg plus gemcitabine (infusion) at 1000 mg/m2 once weekly for 3 weeks of a 28 day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus gemcitabine
Description: Daily Oral placebo/IPI-926 160 mg plus gemcitabine infusion at 1000 mg/m2 once every 3 weeks in a 28 day cycle
Study: NCT05810909

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: amorphous calcium carbonate/ Placebo
Description: The dosage was 1000 mg calcium carbonate (400mg calcium element) per day, and placebo (calcium carbonate change to excipient)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: amorphous calcium carbonate/ Placebo
Description: The dosage was 1000 mg calcium carbonate (400mg calcium element) per day, and placebo (calcium carbonate change to excipient)
Study: NCT01635270

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: mid-position radiation strategy
Description: The midP strategy defines the target as the time weighted average tumor position (mid-position) plus an additional margin, computed specifically for each patient, that takes into account the tumor motion in each direction. This strategy can help to safely reduce toxicity while preserving treatment efficacy
Study: NCT05693688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atosiban
Description: atosiban i.v. administred for 48 hours. The medication will be administered by a bolus injection of 6.75 mg/0.9 mL in 1 min followed by a continuous infusion of 18 mg/hour for 3 hours followed by a continuous infusion of 6 mg/hour for the remaining 45 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atosiban
Description: atosiban i.v. administred for 48 hours. The medication will be administered by a bolus injection of 6.75 mg/0.9 mL in 1 min followed by a continuous infusion of 18 mg/hour for 3 hours followed by a continuous infusion of 6 mg/hour for the remaining 45 hours.
Study: NCT02744560

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: spirulina
Description: Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
Study: NCT00121680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7080
Description: Oral.
Study: NCT03039049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin 0.1 mg
Description: a single dose of Triptorelin 0.1 mg subcutaneously administered 6 days after oocyte retrieval.
Study: NCT04713111

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle (Meditation)
Description: Those in the meditation arm (exercisers) were instructed to complete meditation sessions from the smartphone app, Headspace 2 or more times a week for a duration of 4 weeks.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle (Exercise)
Description: Those in the physical activity arm (meditators) were instructed to complete 30 minutes to 1 hour of physical activity for 2 or more sessions per week for 4 weeks.
Study: NCT01894334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulinastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone
Study: NCT00829660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: The participants were given one tablet (50mg) of acarbose per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day (50mg twice a day i.e. 100mg/day) and then three tablets/day (50mg three times a day i.e. 150mg/day) thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 150mg/day).
Study: NCT01635270

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: ITV
Description: The ITV strategy is the conventional one. It consists in defining the target as the volume covering the whole tumor motion.
Study: NCT03862612

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: regional anaesthesia with Levobupivicaine 0.25% 30mls with two methods either erector spinae plane block or serratus anterior plane block
Description: Erector Spinae Plane Block will be compared to the Serratus Anterior Plane Block in patients undergoing Video assissted thoracic surgery
Study: NCT00829660

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: The participants were given one tablet of matching placebo per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day and then three tablets/day thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 3 tablets/day).
Study: NCT03163173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4419
Description: 30 mg (\~100 μCi) dose of \[14C\]GC4419
Study: NCT00133172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: IV
Study: NCT03997760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-755
Description: Participants will receive TAK-755 as a single IV infusion at one of the 3 dose levels of 40 IU/kg, 80 IU/kg, or 160 IU/kg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to TAK-755 of the 3 dose levels of 40 IU/kg, 80 IU/kg, and 160 IU/kg as single IV infusion.
Study: NCT02738580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COS with GnRH antagonists and rFSH
Description: Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.
Study: NCT03862612

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regional anaesthesia with Levobupivicaine 0.25% 30mls with two methods either erector spinae plane block or serratus anterior plane block
Description: Erector Spinae Plane Block will be compared to the Serratus Anterior Plane Block in patients undergoing Video assissted thoracic surgery
Study: NCT02738580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COS with GnRH antagonists and HP-HMG
Description: Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG in women with normal ovarian function.
Study: NCT03382197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nebulization
Description: For inhalation of the radioaerosol a dose of DTPA-Tc99m (methionine-labeled diethylnitriaminepentaacetic acid) with 1mCi activity, associated with 10 drops of Fenoterol Bromide and 20 drops of Ipatropium Bromide diluted for a total of up to 3 ml of saline solution 0.9%. A MESH vibrating nebulizer (NIVO, Philips Respironics, Murrysville, Pennsylvania) will be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure valve
Description: For nebulization associated with the EPAP valve will be used a non-invasive distribution system consisting of a non-toxic orofacial mask connected to a spring loaded EPAP valve. This mask will be secured to the patient's face through tabs in order to prevent leakage and to maintain proper pressurizing and better patient adaptation.
Study: NCT01701362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: capsules, 150-600 mg/day administered in divided doses twice a day for 15 weeks after randomization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsules, placebo for pregabalin administered in divided doses twice a day for 15 weeks after randomization
Study: NCT01717196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: different volume aspiration
Description: comparison between diagnostic yield of FNA on solid pancreatic masses performed with different aspiration volume (10 and 20ml) and without aspiration.
Study: NCT02973139

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Thoracoscopy
Description: Medical thoracoscopy will be performed as per standard protocols.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fibrinolytic Group
Description: Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 doses
Study: NCT02641756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment interruption after in depth sampling under CART
Description: The participants will undergo in depth sampling under CART to characterise the HIV reservoir in different anatomical compartments. Subsequently an experimental viral rebound, by a brief therapy stop, will help us identify the clinically relevant viral reservoir by doing phylogenetic analysis on the rebounding virus and on the virus found in the different compartments under CART.